Andres E Dulcey
Overview
Explore the profile of Andres E Dulcey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chandia-Cristi A, Gutierrez D, Dulcey A, Lara M, Vargas L, Lin Y, et al.
Cell Rep
. 2024 Apr;
43(5):114144.
PMID: 38656874
The molecular mechanisms underlying seizure generation remain elusive, yet they are crucial for developing effective treatments for epilepsy. The current study shows that inhibiting c-Abl tyrosine kinase prevents apoptosis, reduces...
2.
Sarkar R, Bolel P, Kapoor A, Eliseeva E, Dulcey A, Templin J, et al.
J Clin Endocrinol Metab
. 2024 Feb;
109(9):2306-2316.
PMID: 38421044
Context: Thyroid-stimulating hormone (or thyrotropin) receptor (TSHR) could be a selective target for small molecule ligands to treat thyroid cancer (TC). Objective: We report a novel, orally efficacious ligand for...
3.
Martinez A, Lamaizon C, Valls C, Llambi F, Leal N, Fitzgerald P, et al.
Antioxidants (Basel)
. 2023 Nov;
12(11).
PMID: 38001860
The endoplasmic reticulum is a subcellular organelle key in the control of synthesis, folding, and sorting of proteins. Under endoplasmic reticulum stress, an adaptative unfolded protein response is activated; however,...
4.
Leon R, Gutierrez D, Pinto C, Morales C, de la Fuente C, Riquelme C, et al.
Front Aging Neurosci
. 2023 Jun;
15:1180987.
PMID: 37358955
Background: Growing evidence suggests that the non-receptor tyrosine kinase, c-Abl, plays a significant role in the pathogenesis of Alzheimer's disease (AD). Here, we analyzed the effect of c-Abl on the...
5.
Free R, Nilson A, Boldizsar N, Doyle T, Rodriguiz R, Pogorelov V, et al.
ACS Pharmacol Transl Sci
. 2023 Jan;
6(1):151-170.
PMID: 36654757
We have developed and characterized a novel D2R antagonist with exceptional GPCR selectivity - ML321. In functional profiling screens of 168 different GPCRs, ML321 showed little activity beyond potent inhibition...
6.
Marin T, Dulcey A, Campos F, de la Fuente C, Acuna M, Castro J, et al.
Front Cell Dev Biol
. 2022 Apr;
10:844297.
PMID: 35399514
Niemann-Pick type A (NPA) disease is a fatal lysosomal neurodegenerative disorder caused by the deficiency in acid sphingomyelinase (ASM) activity. NPA patients present severe and progressive neurodegeneration starting at an...
7.
Ma C, Imamura M, Talley D, Rolt A, Xu X, Wang A, et al.
Nat Microbiol
. 2020 Sep;
5(12):1532-1541.
PMID: 32868923
Fluoxazolevir is an aryloxazole-based entry inhibitor of hepatitis C virus (HCV). We show that fluoxazolevir inhibits fusion of HCV with hepatic cells by binding HCV envelope protein 1 to prevent...
8.
Hall M, Marshall T, Kwit A, Miller Jenkins L, Dulcey A, Madigan J, et al.
J Biol Chem
. 2020 Mar;
295(13):4370.
PMID: 32221035
No abstract available.
9.
Singh A, Dashnyam M, Chim B, Escobar T, Dulcey A, Hu X, et al.
Sci Rep
. 2020 Mar;
10(1):3766.
PMID: 32111885
Th17 cells are critical drivers of autoimmune diseases and immunopathology. There is an unmet need to develop therapies targeting pathogenic Th17 cells for the treatment of autoimmune disorders. Here, we...
10.
Goldsborough A, Handley M, Dulcey A, Pluchino K, Kannan P, Brimacombe K, et al.
J Med Chem
. 2020 Feb;
63(3):1443.
PMID: 32013420
No abstract available.